SCHEMBL21892064

SCHEMBL21892064

CCCC(=O)NCCCN1C(=O)CC(C)C1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP2 P42575 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 1/20 0.40
HTT P42858 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
OPRD1 P41143 1/20 0.37
GPR84 Q9NQS5 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15030946 0.91 SMN1; SMN2 (0.42) CASP2SMN1; SMN2HPGDHTTHDAC3
SCHEMBL19704264 0.90 CASP2 (0.45) CASP2SMN1; SMN2HPGDHTTHDAC3
SCHEMBL19703758 0.89 SMN1; SMN2 (0.43) SMN1; SMN2HPGDHTTHDAC3HDAC4
SCHEMBL2625073 0.89 TP53 (0.41) CASP2SMN1; SMN2HPGDHTTHDAC3
SCHEMBL19704262 0.88 HPGD (0.46) CASP2SMN1; SMN2HPGDHTTHDAC3
SCHEMBL18704703 0.88 SMN1; SMN2 (0.49) CASP2SMN1; SMN2HPGDHTTHDAC3
SCHEMBL21892048 0.88 SMN1; SMN2 (0.49) CASP2SMN1; SMN2HPGDHTTHDAC3
SCHEMBL19703757 0.88 SMN1; SMN2 (0.48) SMN1; SMN2HPGDHTTHDAC3HDAC4
SCHEMBL19703805 0.88 CASP2 (0.46) CASP2SMN1; SMN2HPGDHDAC3HDAC4
SCHEMBL19704265 0.87 HPGD (0.48) CASP2SMN1; SMN2HPGDHTTHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10624967-B2 Targeted conjugates and particles and formulations thereof TARVEDA THERAPEUTICS, INC. (US) 2020-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10624967-B2 Targeted conjugates and particles and formulations thereof SSTR5, SSTR1, SSTR4 CASP2 1823/4885SMN1; SMN2 966/4885HPGD 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.